1
|
Auersperg N, Wong AS, Choi KC, Kang SK and
Leung PC: Ovarian surface epithelium: Biology, endocrinology, and
pathology. Endocr Rev. 22:255–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Ozols RF: Treatment goals in OC. Int J
Gynecol Cancer. 15 Suppl 1:S3–S11. 2005. View Article : Google Scholar
|
5
|
Schink JC: Current initial therapy of
stage III and IV OC: challenges for managed care. Semin Oncol. 26(1
Suppl 1): S2–S7. 1999.
|
6
|
Lin L, Miller CT, Contreras JI, Prescott
MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, et
al: The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1),
on chromosome band 14q13 is amplified and overexpressed in
esophageal and lung adenocarcinomas. Cancer Res. 62:5273–5279.
2002.PubMed/NCBI
|
7
|
Wolf I, Bose S, Williamson EA, Miller CW,
Karlan BY and Koeffler HP: FOXA1: Growth inhibitor and a favorable
prognostic factor in human breast cancer. Int J Cancer.
120:1013–1022. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Lantz KA and Kaestner KH: Winged-helix
transcription factors and pancreatic development. Clin Sci (Lond).
108:195–204. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Costa RH, Grayson DR and Darnell JE Jr:
Multiple hepatocyte-enriched nuclear factors function in the
regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell
Biol. 9:1415–1425. 1989. View Article : Google Scholar : PubMed/NCBI
|
10
|
Lai E, Prezioso VR, Smith E, Litvin O,
Costa RH and Darnell JE Jr: HNF-3A, a hepatocyte-enriched
transcription factor of novel structure is regulated
transcriptionally. Genes Dev. 4:1427–1436. 1990. View Article : Google Scholar : PubMed/NCBI
|
11
|
Carroll JS and Brown M: Estrogen receptor
target gene: An evolving concept. Mol Endocrinol. 20:1707–1714.
2006. View Article : Google Scholar : PubMed/NCBI
|
12
|
Friedman JR and Kaestner KH: The Foxa
family of transcription factors in development and metabolism. Cell
Mol Life Sci. 63:2317–2328. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Lee CS, Friedman JR, Fulmer JT and
Kaestner KH: The initiation of liver development is dependent on
Foxa transcription factors. Nature. 435:944–947. 2005. View Article : Google Scholar : PubMed/NCBI
|
14
|
Besnard V, Wert SE, Hull WM and Whitsett
JA: Immunohistochemical localization of Foxa1 and Foxa2 in mouse
embryos and adult tissues. Gene Expr Patterns. 5:193–208. 2004.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Cirillo LA, Lin FR, Cuesta I, Friedman D,
Jarnik M and Zaret KS: Opening of compacted chromatin by early
developmental transcription factors HNF3 (FoxA) and GATA-4. Mol
Cell. 9:279–289. 2002. View Article : Google Scholar : PubMed/NCBI
|
16
|
Gualdi R, Bossard P, Zheng M, Hamada Y,
Coleman JR and Zaret KS: Hepatic specification of the gut endoderm
in vitro: Cell signaling and transcriptional control. Genes Dev.
10:1670–1682. 1996. View Article : Google Scholar : PubMed/NCBI
|
17
|
Nakshatri H and Badve S: FOXA1 as a
therapeutic target for breast cancer. Expert Opin Ther Targets.
11:507–514. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Nucera C, Eeckhoute J, Finn S, Carroll JS,
Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, et al:
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin
Cancer Res. 15:3680–3689. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Badve S, Turbin D, Thorat MA, Morimiya A,
Nielsen TO, Perou CM, Dunn S, Huntsman DG and Nakshatri H: FOXA1
expression in breast cancer-correlation with luminal subtype A and
survival. Clin Cancer Res. 13:4415–4421. 2007. View Article : Google Scholar : PubMed/NCBI
|
20
|
Thorat MA, Marchio C, Morimiya A, Savage
K, Nakshatri H, Reis-Filho JS and Badve S: Forkhead box A1
expression in breast cancer is associated with luminal subtype and
good prognosis. J Clin Pathol. 61:327–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Lupien M, Eeckhoute J, Meyer CA, Wang Q,
Zhang Y, Li W, Carroll JS, Liu XS and Brown M: FoxA1 translates
epigenetic signatures into enhancer-driven lineage-specific
transcription. Cell. 132:958–970. 2008. View Article : Google Scholar : PubMed/NCBI
|
22
|
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J,
Chen Z, Beroukhim R, Wang H, Lupien M, et al: Androgen receptor
regulates a distinct transcription program in androgen-independent
prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zeppernick F and Meinhold-Heerlein I: The
new FIGO staging system for ovarian, fallopian tube and primary
peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Hauptmann S, du Bois A, Meinhold-Herlein
I, Pfisterer J and Avril S: Histological grading of epithelial
ovarian cancer. Review and recommendation. Pathologe. 35:497–503.
2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Vinayagamoorthy T, Maryanski D,
Vinayagamoorthy D, Hay KS, Yo J, Carter M and Wiegel J: Improved
internal control for molecular diagnosis assays. MethodsX.
2:159–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
26
|
Kaestner KH, Knochel W and Martinez DE:
Unified nomenclature for the winged helix/forkhead transcription
factors. Genes Dev. 14:142–146. 2000.PubMed/NCBI
|
27
|
Lehmann OJ, Sowden JC, Carlsson P, Jordan
T and Bhattacharya SS: Fox's in development and disease. Trend
Genet. 19:339–344. 2003. View Article : Google Scholar
|
28
|
Tan Y, Raychaudhuri P and Costa RH: Chk2
mediates stabilization of the FoxM1 transcription factor to
stimulate expression of DNA repair genes. Mol Cell Biol.
27:1007–1016. 2007. View Article : Google Scholar : PubMed/NCBI
|
29
|
Robinson JL and Carroll JS: FoxA1 is a key
mediator of hormonal response in breast and prostate cancer. Front
Endocrinol (Lausanne). 3:682012.PubMed/NCBI
|